{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:06:44Z","timestamp":1775153204598,"version":"3.50.1"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Controlled human infection models can play an important role in vaccine development, particularly for neglected tropical diseases such as helminth infections. Currently, controlled infection models have been established for schistosomiasis and hookworm. This review highlights the developments in the controlled human schistosomiasis infection model (CHI-S) and the controlled human hookworm infection model (CHHI) and their contributions to vaccine development. In general, both models are considered safe and well-tolerated. Measures to decrease risk of potential adverse events were taken when developing the models. For both models, production of challenge agents follows the principles of Good Manufacturing Practice. Both models have proven to reliably detect infection and can be used to assess efficacy of immunization strategies. While hookworms and schistosomes are both helminths, the controlled human infection (CHI)-studies have also highlighted differences between these pathogens. Notably, schistosomiasis seems to induce more, dose-dependent, systemic symptoms, whereas in hookworm models skin symptoms are much more prominent. Infection levels for schistosomiasis are therefore limited and lower than those usually seen in endemic populations, whereas for hookworm it is possible to reach levels comparable to mild-moderate intensity infection in the field. Host responses to short-term infection were also different: short-term schistosome infection induced immune-tolerance, whereas short-term infection with hookworm larvae seems to induce a more pro-inflammatory response compared to that seen in the adult worms. Most studies have been performed in na\u00efve non-endemic populations, however, currently the models are being expanded to endemic areas. This has raised new questions around the impact of non-native strains of parasites or vectors to the endemic parasite strains and the environment. Studies in endemic areas, however, will significantly contribute towards understanding the immunology of these helminth infections in pre-exposed individuals. In general, the success of these established models is encouraging to the further development of controlled human helminth infection models.<\/jats:p>","DOI":"10.1371\/journal.pntd.0014137","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:36:56Z","timestamp":1775151416000},"page":"e0014137","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in vaccine development through the controlled human infection models for hookworm and schistosomiasis"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-3380","authenticated-orcid":true,"given":"Marie-Astrid","family":"Hoogerwerf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses","family":"Egesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selidgji Todagbe","family":"Agnandji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Loukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meta","family":"Roestenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"7","key":"pntd.0014137.ref001","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"TC Darton","year":"2015","journal-title":"The Lancet Infectious Diseases"},{"issue":"6","key":"pntd.0014137.ref002","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"DM Gordon","year":"1995","journal-title":"J Infect Dis"},{"issue":"11","key":"pntd.0014137.ref003","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor","volume":"62","author":"WH Chen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"pntd.0014137.ref004","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fmed.2018.00297","article-title":"Controlled human infections as a tool to reduce uncertainty in clinical vaccine Development","volume":"5","author":"M Roestenberg","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"10440","key":"pntd.0014137.ref005","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","article-title":"Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"pntd.0014137.ref006","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14760584.2024.2410893","article-title":"Hookworm vaccines: current and future directions","volume":"23","author":"ER Sarkar","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"pntd.0014137.ref007","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2023.05.013","article-title":"Vaccine value profile for Hookworm","volume":"42","author":"KP Puchner","year":"2024","journal-title":"Vaccine"},{"key":"pntd.0014137.ref008","doi-asserted-by":"crossref","first-page":"16088","DOI":"10.1038\/nrdp.2016.88","article-title":"Hookworm infection","volume":"2","author":"A Loukas","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"pntd.0014137.ref009","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30177-4","article-title":"Experimental infection of human volunteers","volume":"18","author":"M Roestenberg","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"pntd.0014137.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009908","article-title":"Experimental human hookworm infection: a narrative historical review","volume":"15","author":"PR Chapman","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0014137.ref011","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2222.2009.03433.x","article-title":"Experimental hookworm infection: a randomized placebo-controlled trial in asthma","volume":"40","author":"JR Feary","year":"2010","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"pntd.0014137.ref012","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000274","article-title":"Randomized, placebo controlled trial of experimental hookworm infection for improving gluten tolerance in celiac disease","volume":"11","author":"J Croese","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"pntd.0014137.ref013","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1038\/s41467-023-40263-4","article-title":"Effect of experimental hookworm infection on insulin resistance in people at risk of type 2 diabetes","volume":"14","author":"DR Pierce","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"pntd.0014137.ref014","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/infdis\/jiaa414","article-title":"A randomized controlled trial to investigate safety and variability of egg excretion after repeated controlled human hookworm infection","volume":"223","author":"M-A Hoogerwerf","year":"2021","journal-title":"J Infect Dis"},{"issue":"5","key":"pntd.0014137.ref015","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy083","article-title":"Controlled human hookworm infection: accelerating human hookworm vaccine development","volume":"5","author":"D Diemert","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"pntd.0014137.ref016","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41591-020-0759-x","article-title":"A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics","volume":"26","author":"MCC Langenberg","year":"2020","journal-title":"Nat Med"},{"key":"pntd.0014137.ref017","doi-asserted-by":"crossref","first-page":"101746","DOI":"10.1016\/j.biologicals.2024.101746","article-title":"Regulatory workshop on challenge strain development and GMP manufacture \u2013 a stakeholder meeting report","volume":"85","author":"N Corti","year":"2024","journal-title":"Biologicals"},{"key":"pntd.0014137.ref018","volume-title":"Considerations on the principles of development and manufacturing qualities of challenge agents for use in human infection models","author":"BA La C","year":"2022"},{"key":"pntd.0014137.ref019","unstructured":"Organisation WH. Schistosomiasis and soiltransmitted helminthiases: progress report, 2021. 2022."},{"issue":"1","key":"pntd.0014137.ref020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-018-0013-8","article-title":"Schistosomiasis","volume":"4","author":"DP McManus","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"pntd.0014137.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243224","article-title":"A systematic review and meta-analysis on the rate of human schistosomiasis reinfection","volume":"15","author":"A Zacharia","year":"2020","journal-title":"PLoS One"},{"key":"pntd.0014137.ref022","doi-asserted-by":"crossref","first-page":"104832","DOI":"10.1016\/j.ebiom.2023.104832","article-title":"Safety and infectivity of female cercariae in Schistosoma-na\u00efve, healthy participants: a controlled human Schistosoma mansoni infection study","volume":"97","author":"JPR Koopman","year":"2023","journal-title":"EBioMedicine"},{"issue":"4","key":"pntd.0014137.ref023","article-title":"Clinical tolerance but no protective efficacy in a placebo-controlled trial of repeated controlled schistosome infection","volume":"135","author":"JPR Koopman","year":"2024","journal-title":"J Clin Invest"},{"issue":"7","key":"pntd.0014137.ref024","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/infdis\/jiy275","article-title":"Establishing the production of male Schistosoma mansoni cercariae for a controlled human infection model","volume":"218","author":"JJ Janse","year":"2018","journal-title":"J Infect Dis"},{"issue":"14","key":"pntd.0014137.ref025","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1017\/S0031182014000626","article-title":"Tools for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays and upconverting phosphor labels","volume":"141","author":"PLAM Corstjens","year":"2014","journal-title":"Parasitology"},{"issue":"3","key":"pntd.0014137.ref026","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0035-9203(89)90507-5","article-title":"Circulating anodic antigen levels in serum before and after chemotherapy with praziquantel in schistosomiasis mansoni","volume":"83","author":"N de Jonge","year":"1989","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0014137.ref027","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1017\/S0031182000077386","article-title":"Monitoring the efficacy of different doses of praziquantel by quantification of circulating antigens in serum and urine of schistosomiasis patients","author":"L van Lieshout","year":"1994","journal-title":"Parasitology"},{"issue":"10","key":"pntd.0014137.ref028","doi-asserted-by":"crossref","first-page":"732","DOI":"10.7326\/L18-0438","article-title":"Katayama syndrome without Schistosoma mansoni eggs","volume":"170","author":"MCC Langenberg","year":"2019","journal-title":"Ann Intern Med"},{"issue":"1","key":"pntd.0014137.ref029","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-62144-8","article-title":"T cell responses in repeated controlled human schistosome infection compared to natural exposure","volume":"16","author":"E Driciru","year":"2025","journal-title":"Nat Commun"},{"issue":"97","key":"pntd.0014137.ref030","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adl1965","article-title":"Early symptom-associated inflammatory responses shift to type 2 responses in controlled human schistosome infection","volume":"9","author":"EL Houlder","year":"2024","journal-title":"Sci Immunol"},{"key":"pntd.0014137.ref031","doi-asserted-by":"crossref","first-page":"635985","DOI":"10.3389\/fimmu.2021.635985","article-title":"Immunological considerations for schistosoma vaccine development: transitioning to endemic settings","volume":"12","author":"E Driciru","year":"2021","journal-title":"Front Immunol"},{"key":"pntd.0014137.ref032","doi-asserted-by":"crossref","first-page":"2","DOI":"10.12688\/aasopenres.12841.2","article-title":"Ethical and scientific considerations on the establishment of a controlled human infection model for schistosomiasis in Uganda: report of a stakeholders\u2019 meeting held in Entebbe, Uganda","volume":"1","author":"AM Elliott","year":"2018","journal-title":"AAS Open Res"},{"key":"pntd.0014137.ref033","doi-asserted-by":"crossref","first-page":"17","DOI":"10.12688\/aasopenres.12972.1","article-title":"Risk assessment for the implementation of controlled human Schistosoma mansoni infection trials in Uganda","volume":"2","author":"JP Koopman","year":"2019","journal-title":"AAS Open Res"},{"issue":"1","key":"pntd.0014137.ref034","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/11287462.2022.2091503","article-title":"Ethical and practical considerations arising from community consultation on implementing controlled human infection studies using Schistosoma mansoni in Uganda","volume":"33","author":"M Egesa","year":"2022","journal-title":"Global Bioeth"},{"issue":"1","key":"pntd.0014137.ref035","article-title":"Global distribution of human hookworm species and differences in their morbidity effects: a systematic review","volume":"3","author":"ACA Clements","year":"2022","journal-title":"Lancet Microbe"},{"issue":"12","key":"pntd.0014137.ref036","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S1473-3099(21)00153-5","article-title":"Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial","volume":"21","author":"PR Chapman","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"pntd.0014137.ref037","first-page":"367","article-title":"Controlled infection of humans with the hookworm parasite Necator americanus to accelerate vaccine development\u00a0: the Human Hookworm Vaccination\/Challenge Model (HVCM)","volume":"445","author":"DI Pritchard","year":"2024","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6","key":"pntd.0014137.ref038","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/infdis\/jiz218","article-title":"New insights into the kinetics and variability of egg excretion in controlled human hookworm infections","volume":"220","author":"M-A Hoogerwerf","year":"2019","journal-title":"J Infect Dis"},{"issue":"12","key":"pntd.0014137.ref039","article-title":"Protective efficacy of short-term infection with Necator americanus hookworm larvae in healthy volunteers in the Netherlands: a single-centre, placebo-controlled, randomised, controlled, phase 1 trial","volume":"4","author":"M-A Hoogerwerf","year":"2023","journal-title":"Lancet Microbe"},{"issue":"5","key":"pntd.0014137.ref040","first-page":"508","article-title":"Immunity of dogs to ancylostoma braziliense infection following vaccination with X-irradiated Ancylostoma caninum larvae","volume":"150","author":"TA Miller","year":"1967","journal-title":"J Am Vet Med Assoc"},{"key":"pntd.0014137.ref041","doi-asserted-by":"crossref","first-page":"877707","DOI":"10.3389\/fimmu.2022.877707","article-title":"Not all worms were created equal","volume":"13","author":"A Loukas","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"pntd.0014137.ref042","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13071-022-05371-y","article-title":"The production of Necator americanus larvae for use in experimental human infection","volume":"15","author":"PR Chapman","year":"2022","journal-title":"Parasit Vectors"},{"issue":"1","key":"pntd.0014137.ref043","doi-asserted-by":"crossref","first-page":"2416517","DOI":"10.1080\/19490976.2024.2416517","article-title":"Controlled infection with cryopreserved human hookworm induces CTLA-4 expression on Tregs and upregulates tryptophan metabolism","volume":"16","author":"F Vacca","year":"2024","journal-title":"Gut Microbes"},{"issue":"5","key":"pntd.0014137.ref044","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/ibd\/izad110","article-title":"Controlled hookworm infection for medication-free maintenance in patients with ulcerative colitis: a pilot, double-blind, randomized control trial","volume":"30","author":"TC Mules","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"pntd.0014137.ref045","doi-asserted-by":"crossref","first-page":"107592","DOI":"10.1016\/j.micpath.2025.107592","article-title":"Manufacture of Necator americanus as an infectious challenge agent: accelerating human hookworm vaccine development","volume":"204","author":"G Erwin","year":"2025","journal-title":"Microb Pathog"},{"issue":"1","key":"pntd.0014137.ref046","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13690-021-00650-z","article-title":"Establishing a controlled hookworm human infection (CHHI) model for Africa: a report from the stakeholders meeting held in Lambar\u00e9n\u00e9, Gabon, November 10-11, 2019","volume":"79","author":"A Alabi","year":"2021","journal-title":"Arch Public Health"},{"issue":"4","key":"pntd.0014137.ref047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012049","article-title":"Serological diagnosis of soil-transmitted helminth (Ascaris, Trichuris and hookworm) infections: a scoping review","volume":"18","author":"S Roose","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0014137.ref048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008237","article-title":"Comprehensive analysis of the secreted proteome of adult Necator americanus hookworms","volume":"14","author":"J Logan","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0014137.ref049","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaci.2014.07.022","article-title":"Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease","volume":"135","author":"J Croese","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"pntd.0014137.ref050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/ng.2875","article-title":"Genome of the human hookworm Necator americanus","volume":"46","author":"YT Tang","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"pntd.0014137.ref051","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/s41467-024-50313-0","article-title":"Controlled human hookworm infection remodels plasmacytoid dendritic cells and regulatory T cells towards profiles seen in natural infections in endemic areas","volume":"15","author":"MD Manurung","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"pntd.0014137.ref052","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.04.027","article-title":"Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths","volume":"130","author":"DJ Diemert","year":"2012","journal-title":"J Allergy Clin Immunol"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:37:03Z","timestamp":1775151423000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014137"}},"subtitle":[],"editor":[{"given":"Vito","family":"Colella","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0014137","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}